Tuesday, February 26, 2008 6:26:01 AM
<Actually, I did not specify probabilities that the IND would be accepted or rejected>
Actually, you just said the fact that they wanted a new IND was scary. So, I would place a pretty high value on the probability NON ACCEPTANCE in just that term alone. Scary, means that fear is involved and the only thing that would really HURT is if the FDA said "no". That would be the only scary scenario.
What's really comical is that you mentioned "trial design" in your first post acceptance comment on the matter, yet there hasn't been any follow up comments. Was that just because you thought it better just to leave it at a vague "trial design" comment and see what trouble that would stir up? FUD without the FUD?
Actually, you just said the fact that they wanted a new IND was scary. So, I would place a pretty high value on the probability NON ACCEPTANCE in just that term alone. Scary, means that fear is involved and the only thing that would really HURT is if the FDA said "no". That would be the only scary scenario.
What's really comical is that you mentioned "trial design" in your first post acceptance comment on the matter, yet there hasn't been any follow up comments. Was that just because you thought it better just to leave it at a vague "trial design" comment and see what trouble that would stir up? FUD without the FUD?
Recent RPRX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/28/2026 08:48:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/28/2026 08:01:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/26/2026 09:49:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 01:20:12 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/20/2026 08:23:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/15/2026 08:38:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/14/2026 09:22:49 PM
- Form 13F-NT - Quarterly report filed by institutional managers, Notice • Edgar (US Regulatory) • 05/14/2026 06:29:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2026 09:14:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2026 09:12:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2026 09:10:50 PM
- Royalty Pharma to present at upcoming investor conferences • GlobeNewswire Inc. • 05/07/2026 08:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/06/2026 01:04:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:31:54 AM
- Royalty Pharma reports first quarter 2026 results • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/30/2026 09:54:06 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/28/2026 09:00:16 PM
- Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation • GlobeNewswire Inc. • 04/21/2026 05:00:00 PM
- Royalty Pharma Declares Second Quarter 2026 Dividend • GlobeNewswire Inc. • 04/17/2026 12:30:00 PM
- Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026 • GlobeNewswire Inc. • 04/15/2026 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/13/2026 01:53:04 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/10/2026 08:11:03 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 08:10:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 09:58:57 PM
